stars 1 stars 2 stars 3

Immunexpress is a privately owned company creating revolutionary molecular diagnostics for sepsis. The company has offices in Seattle, USA and Brisbane, Australia. Immunexpress's product pipeline aims to address the overwhelming unmet clinical needs of sepsis patients, as well as clinicians, payers and healthcare systems. Unlike the traditional approach to sepsis diagnosis, SeptiCyte® quantifies the specific molecular biomarkers from a patient's immune system ('host response'). Biomarkers capture signals from a patient's immune system in response to infection. These biomarkers may hold the key to early detection of sepsis, as well as guiding the use and timing of drugs and other therapies.

Immunexpress Inc. Questions

The Immunexpress Inc. annual revenue was $6 million in 2026.

Rollie Carlson is the CEO of Immunexpress Inc..

13 people are employed at Immunexpress Inc..

Immunexpress Inc. is based in Seattle, Washington.

The NAICS codes for Immunexpress Inc. are [541, 62, 54171, 621, 541711, 6215, 5417, 62151, 54].

The SIC codes for Immunexpress Inc. are [8071, 80, 807].

Top Immunexpress Inc. Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users